花旗发表研究报告指，翰森制药(03692.HK) 去年收入按年升21.3%至123亿元人民币，略高于该行及市场预期介乎1%至2%；纯利按年升33.4%至44亿元人民币，高于该行预期达一成。期内创新药物及抗体偶联药物(ADC)等收入按年升38.1%至约95亿元人民币，期内毛利率扩至91%。
该行指，管理层提供今年收入呈双位数增长。该行表示，将公司今年收入及每股盈利预测分别上调6.9%及13.8%，明年收入及每股盈利预测则分别上调8.3%及14.9%。该行将其目标价由28.5元上调至32元，维持其评级为“买入”。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-24 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.